Vistagen Therapeutics: Will It Ever Recover?

Vistagen Therapeutics (OTC: VSTA) has declined a steep 9.82% today, shaving off overall returns for 2012 year-to-date. Since New Year’s Day, Vistagen Therapeutics has dropped 66.89%.

Vistagen Therapeutics opened today’s over-the-counter trading at a share price of $1.13. By afternoon trading, the price had dropped precipitously to close at $1.01.Vistagen Therapeutics has been declining steadily the whole year. The share drop has been steep since April 13 and has become more disheartening over recent weeks.

Vistagen Therapeutics is involved in the field of drug rescue and cell therapy. The company also applies its expertise to therapeutic cell research.

Vistagen Therapeutics secures vital U.S. patent for stem cell investigation and has been awarded patent 11/445,733. This patent incorporates the methods of measuring forms of poisonous outcomes potentially reduced by trial drugs in the stems of liver cells. Also included in patent 11/445,733 is the authority to utilize all cells derived small rodent liver cells, including rats and mice.

Next line permission is also granted for testing cells in ‘vivo’ organism or produced from cells taken from embryos and cells from pluripotent provoked sources. The company can also monitor toxic changes in genes. This patent permits the company to monitor changes in the genes as a way of predicting drug toxins.

On May 14, 2012, the company issued an update letter in a PR to stockholders, including an associated SEC Form 8-K filing.

Vistagen Therapeutics’ methods involve drug rescue with its enviable experience in stem cell (pluripotent expertise). Testing is an important part of any drug that cannot be ignored. For the public use, this company is scrutinizing all of its drugs very proficiently then they send it in to the market. All of these drugs were abandoned after indications that they could cause adverse effects on the human heart. This has been corroborated by institutions including N.I.H., drug development companies and academic research laboratories.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.

Recent Stories

SignUp Now For Our Featured Newsletter